title: Characterization of angiotensin receptors mediating prostaglandin synthesis in C6 glioma cells.
abstract: The heptapeptide angiotensin (ANG)-(1-7) mimics some but not all the central actions of ANG II, suggesting that receptor subtypes may exist. The effects of ANG-(1-7), ANG II, and ANG I on prostaglandin (PG) E2 and prostacyclin (PGI2) synthesis were investigated in neurally derived rat C6 glioma cells. All three ANG peptides stimulated PG release in a dose-dependent manner with the order of potency ANG-(1-7) greater than ANG I greater than ANG II. PGE2 release induced by ANG-(1-7) (10(-7) M) was partially blocked by [Sar1,Ile8]ANG II (10(-6) M), [Sar1,Thr8]ANG II (10(-6) M), or the subtype 1 selective antagonist Du Pont 753 (10(-5) M) but not by the subtype 2 selective antagonist CGP 42112A (10(-7)-10(-5) M). PGI2 release was inhibited only by [Sar1,Thr8]ANG II. ANG II-induced PGE2 release was blocked by [Sar1,Thr8]ANG II (10(-6) M), [Sar1,Ile8]ANG II (10(-6) M), or Du Pont 753 (10(-7) M) but not by CGP 42112A (10(-7)-10(-5) M). In contrast, ANG II-induced PGI2 release was blocked by Du Pont 753 (10(-7) M) as well as [Sar1,Ile8]ANG II (10(-6) M) but not by [Sar1,Thr8]ANG II or CGP 42112A. Thus ANG II-stimulated PGE2 and PGI2 syntheses in C6 glioma cells are mediated via receptor subtype 1. ANG-(1-7)-induced PGE2 synthesis is also mediated via subtype 1 receptors; however, PGI2 release was blocked by [Sar1,Thr8]ANG II only.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Brain and Vascular Research, Cleveland Clinic Foundation, Ohio 44195-5070.
authors.forename: N
authors.initials: N
authors.lastname: Jaiswal
authors.forename: D I
authors.initials: DI
authors.lastname: Diz
authors.forename: E A
authors.initials: EA
authors.lastname: Tallant
authors.forename: M C
authors.initials: MC
authors.lastname: Khosla
authors.forename: C M
authors.initials: CM
authors.lastname: Ferrario
mesh_terms: D000803:Angiotensin I / Q000494:pharmacology; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000494:pharmacology; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D005910:Glioma / Q000378:metabolism* / Q000473:pathology; D007093:Imidazoles / Q000494:pharmacology; D019808:Losartan; D009842:Oligopeptides / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D011453:Prostaglandins / Q000096:biosynthesis*; D011945:Receptors, Angiotensin / Q000502:physiology*; D013777:Tetrazoles / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D057911:Angiotensin Receptor Antagonists; D007093:Imidazoles; D009842:Oligopeptides; D010446:Peptide Fragments; D011453:Prostaglandins; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D000804:Angiotensin II; C060894:CGP 42112A; D000803:Angiotensin I; C118790:angiotensin I (1-7); D019808:Losartan